Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
|
|
|
5.
|
|
|
|
6.
|
|
|
|
7.
|
|
|
|
8.
|
|
|
|
9.
|
|
|
|
10.
|
|
|
|
11.
|
|
|
|
12.
|
|
|
|
13.
|
|
|
|
14.
|
|
|
|
15.
|
|
|
|
16.
|
|
|
|
17.
|
|
|
|
18.
|
|
|
|
19.
|
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. [electronic resource] by
- Kullmann, F
- Hollerbach, S
- Dollinger, M M
- Harder, J
- Fuchs, M
- Messmann, H
- Trojan, J
- Gäbele, E
- Hinke, A
- Hollerbach, C
- Endlicher, E
Producer: 20090424
In:
British journal of cancer vol. 100
Availability: No items available.
|
|
|
20.
|
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. [electronic resource] by
- Kullmann, F
- Hartmann, A
- Stöhr, R
- Messmann, H
- Dollinger, M M
- Trojan, J
- Fuchs, M
- Hollerbach, S
- Harder, J
- Troppmann, M
- Kutscheidt, A
- Endlicher, E
Producer: 20111207
In:
Oncology vol. 81
Availability: No items available.
|